Honda Is Selling More of GM's Electric SUVs Than General Motors
While it's not something either company talks a lot about publicly, the Honda Prologue and Acura ZDX are essentially midsize GM electric SUVs in elaborate trench coats. Underneath their badge-engineered elements, they're fundamentally the same vehicle as the Chevy Blazer EV and Cadillac Lyriq. But despite arriving later and being sold through a smaller network of dealers, Honda's versions are somehow still selling better than the cars they're based on.
The Q2 numbers tell the whole story. Honda's dealers have managed to sell more than 16,000 Prologues so far this year. Meanwhile, Chevy has sold fewer than 13,000 Blazer EVs. Bear in mind, Chevrolet has close to 3,000 dealerships in the United States; Honda doesn't even top 1,100. That means, on average, each Chevy dealership has moved fewer than 4.5 Blazer EVs in 2025; meanwhile, each Honda dealership is averaging more than 15 Prologues.
On the premium side, Acura has racked up 10,335 ZDX sales for the year, to Cadillac's 9,317 Lyriqs. While the ZDX was only the third-best-selling car in Acura's showrooms through Q2, it more than tripled the volume of the (soon to be discontinued) TLX sedan and doubled that of the Integra. We didn't run the numbers on the ratio of Acura dealerships to Cadillac dealerships, but you can probably guess how that shakes out.
In GM's defense, the company is actually moving more Ultium-based models than the above numbers suggest. In addition to Blazer EV and Lyriq, there's also the Cadillac Escalade iQ (3,766), Optiq (4,940), and Vistiq (1,745); and the Chevy Equinox EV (27,749). And that's not even getting into the trucks (GMC Hummer EV, Chevy Silverado EV and GMC Sierra EV). Point being, in terms of sheer Ultium EV sales, GM is moving a lot more metal than Honda, even if Honda is doing better in the segments where their offerings overlap.
There's also plenty of good news on GM's side of this equation. While Blazer EV might be losing the race to Prologue, it's still pacing well ahead of its 2024 sales. In fact, out of GM's entire EV portfolio, only the Lyriq's sales are off compared to last year's. The Cadillac brand, in aggregate, has sold 50% more EVs so far in 2025.
Got a tip? Send it to tips@thedrive.com!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Why Hamilton Insurance Group (HG) Is Up 9.5% After Strong Q2 Results and New Risk Leadership
Hamilton Insurance Group reported strong second quarter results, with revenue rising to US$740.77 million and net income reaching US$187.42 million, while also completing a share buyback of over 4.33 million shares; the company additionally announced Russ Buckley as the incoming Group Chief Risk Officer following Alex Baker's transition to CEO of Hamilton Global Specialty. These developments signal strengthened executive leadership and continued capital management discipline, which together could influence both operational performance and investor sentiment. Next, we'll examine how the robust earnings and new risk leadership may impact Hamilton Insurance Group's long-term investment narrative. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Hamilton Insurance Group Investment Narrative Recap To be a shareholder in Hamilton Insurance Group, you need to believe in the firm's ability to manage risk and seize growth in specialty and reinsurance markets, despite inherent volatility. The strong Q2 results and executive appointments reinforce confidence in the company's operational momentum, but these developments do not substantially reduce the biggest ongoing risk: the unpredictability of large catastrophic losses that could impact earnings and capital strength in the near term. Among the recent news, the appointment of Russ Buckley as Group Chief Risk Officer is particularly relevant, given his experience managing actuarial and risk functions at major global insurers. With Buckley set to oversee Hamilton's risk controls, investors can watch for enhancements in underwriting accuracy and loss management that may help support performance despite market volatility and intense competition in specialty lines. In contrast, investors should not overlook how even with improved earnings and leadership, exposure to unexpected catastrophic events remains a risk that... Read the full narrative on Hamilton Insurance Group (it's free!) Hamilton Insurance Group is projected to reach $3.0 billion in revenue and $536.4 million in earnings by 2028. This outlook relies on an annual revenue growth rate of 5.4% and an earnings increase of $155.9 million from current earnings of $380.5 million. Uncover how Hamilton Insurance Group's forecasts yield a $25.14 fair value, a 3% upside to its current price. Exploring Other Perspectives Four viewpoints from the Simply Wall St Community put Hamilton Insurance Group's fair value between US$11.44 and US$125.75 per share. While many see robust earnings and operational discipline as positives, your own outlook may shift when considering how concentrated exposure to complex, high-severity risks still shapes future results, see how other investors assess these trade-offs. Explore 4 other fair value estimates on Hamilton Insurance Group - why the stock might be worth over 5x more than the current price! Build Your Own Hamilton Insurance Group Narrative Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your Hamilton Insurance Group research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Our free Hamilton Insurance Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hamilton Insurance Group's overall financial health at a glance. No Opportunity In Hamilton Insurance Group? Opportunities like this don't last. These are today's most promising picks. Check them out now: Find companies with promising cash flow potential yet trading below their fair value. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Uncover the next big thing with financially sound penny stocks that balance risk and reward. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include HG. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Can Kemper's (KMPR) $500M Buyback Reveal New Priorities in Capital Allocation Strategy?
Kemper Corporation recently announced that its Board of Directors declared a quarterly dividend of US$0.32 per share, reported its second-quarter and six-month 2025 financial results, and authorized a new share repurchase program of up to US$500 million. In addition to the new buyback, the company provided an update on its completed share repurchases, signaling continued prioritization of shareholder returns through both dividends and share repurchases. We'll explore how the newly authorized US$500 million share repurchase program may reshape Kemper's investment narrative and capital management outlook. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. Kemper Investment Narrative Recap To be a Kemper shareholder, you'd need to believe in the company's ability to convert its scale and specialization in non-standard auto insurance into lasting value, despite a competitive market and earnings volatility. While the new US$500 million share repurchase program reflects a commitment to shareholder returns, it doesn't materially alter the importance of consistent underwriting profitability or cushion against the biggest current risk: moderating revenue growth due to fierce industry competition and pricing pressures. Of the recent announcements, the earnings results for the first half of 2025 stand out. Kemper reported higher year-on-year revenue and net income for the six-month period, suggesting operational momentum. However, this growth comes amid ongoing competition in key markets, keeping pressure on margins and asserting the need for sustained financial discipline even as the company builds on higher retained earnings. But, if increased competition in states like California and Texas continues to erode pricing power and policy retention, investors should be mindful that ... Read the full narrative on Kemper (it's free!) Kemper's narrative projects $5.7 billion revenue and $406.9 million earnings by 2028. This requires 6.2% yearly revenue growth and a $63.5 million earnings increase from $343.4 million currently. Uncover how Kemper's forecasts yield a $67.60 fair value, a 25% upside to its current price. Exploring Other Perspectives Ten fair value estimates from the Simply Wall St Community all point to US$67.60 per share. Against this unanimity, wider competition risks could be a key driver of future divergence in outlooks; see how others are interpreting the signals. Explore another fair value estimate on Kemper - why the stock might be worth as much as 25% more than the current price! Build Your Own Kemper Narrative Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your Kemper research is our analysis highlighting 4 key rewards that could impact your investment decision. Our free Kemper research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kemper's overall financial health at a glance. Looking For Alternative Opportunities? Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters: Find companies with promising cash flow potential yet trading below their fair value. AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Outshine the giants: these 18 early-stage AI stocks could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KMPR. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
13 minutes ago
- Yahoo
Apogee Therapeutics (APGE) Is Up 5.9% After Strong APG777 Phase 2 Data and Accelerated Plans
Apogee Therapeutics recently reported positive 16-week results from its APEX Phase 2 Part A trial, with APG777 meeting all primary and key secondary endpoints in moderate-to-severe atopic dermatitis and showing potential for significantly reduced injection frequency. This progress has led the company to accelerate its clinical timeline, planning Phase 3 studies for APG777 in 2026 and initiating a head-to-head Phase 1b trial comparing APG279 to an established competitor. We'll examine how the accelerated advancement of APG777 in atopic dermatitis could influence Apogee's broader investment story. Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. What Is Apogee Therapeutics' Investment Narrative? For Apogee Therapeutics, the core investment case hinges on belief in its pipeline's potential, particularly APG777 for atopic dermatitis after strong Phase 2 data. The company's accelerated timeline into Phase 3 and an upcoming head-to-head trial signal critical short-term catalysts that could shift perception, especially considering the market's muted reaction so far. However, the expanded losses reported this quarter, coupled with no revenue and extended unprofitability forecasts, reinforce ongoing risks, especially reliance on clinical milestones for future value and eventual commercial success. Recent clinical wins offer momentum, but investors still face the uncertainty of transitioning from promising trial data to real-world uptake and regulatory approval. This news is material to the story, making near- and medium-term trial readouts the main events to watch, but financial pressure has not eased. But, despite recent positive trial results, the absence of meaningful revenue remains a risk investors need to watch. Our valuation report unveils the possibility Apogee Therapeutics' shares may be trading at a premium. Exploring Other Perspectives Across three community fair value estimates, retail investors in the Simply Wall St Community see US$10 to US$100 per share, with one outlier at the upper end. This striking variation shows how much opinions can diverge, and it puts the focus on whether Apogee's cash position can bridge the gap to its next big trial deliverables. Consider these viewpoints as you weigh what might come next for the company. Explore 3 other fair value estimates on Apogee Therapeutics - why the stock might be worth over 2x more than the current price! Build Your Own Apogee Therapeutics Narrative Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your Apogee Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision. Our free Apogee Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Apogee Therapeutics' overall financial health at a glance. Ready For A Different Approach? Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay: The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include APGE. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
